Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 1/20 | 0.38 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.35 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.35 |
| ▸ | PTGES | O14684 | 6/20 | 0.34 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.33 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2797815 | 0.84 | GRM5 (0.38) | GRM5CYP2D6HRH3HRH4PTGES | |
| SCHEMBL3351697 | 0.82 | FFAR1 (0.48) | GRM5TSHRCYP2D6HRH3HRH4 | |
| SCHEMBL8850812 | 0.81 | HRH3 (0.47) | GRM5CYP2D6HRH3HRH4PTGES | |
| SCHEMBL19440746 | 0.81 | CYP2D6 (0.39) | GRM5CYP2D6HRH3HRH4PTGES | |
| SCHEMBL3614755 | 0.80 | GRM5 (0.39) | GRM5ALDH1A1CYP2D6 | |
| SCHEMBL26703935 | 0.79 | TRPA1 (0.39) | GRM5TRPA1ALDH1A1TSHRCYP2D6 | |
| SCHEMBL19442429 | 0.79 | PRMT6 (0.45) | GRM5CYP2D6HRH3HRH4 | |
| SCHEMBL3353828 | 0.79 | GRM5 (0.51) | GRM5CYP2D6HRH3 | |
| SCHEMBL3446231 | 0.78 | FFAR1 (0.49) | ALDH1A1TSHRPTGES | |
| SCHEMBL20630692 | 0.77 | TRPA1 (0.36) | TRPA1ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023009785-A1 | TEAD INHIBITORS AND USES THEREOF | CEDILLA THERAPEUTICS, INC. (US) | 2023-02-02 | — | — | WO | disclosed |